May 23, 2007 — MedicalCV Inc. has announced that the United States Patent and Trademark Office ("USPTO") has issued three additional Notices of Allowance to MedicalCV on patent applications pertaining to various aspects of MedicalCV's proprietary laser-based surgical ablation technology. MedicalCV currently markets both the ATRILAZE and SOLAR Surgical Ablation Systems.
Both the SOLAR and ATRILAZE Surgical Ablation Systems were developed from MedicalCV's laser-based technology with the intent to provide surgeons a versatile ablation platform for the creation of lesions in soft and cardiac tissue. The SOLAR System recently received 510(K) clearance from the FDA for soft tissue ablation and the ATRILAZE System has obtained three separate 510(K) clearances for ablation or coagulation of soft tissue, including cardiac tissue.
However, the treatment indication for cardiac arrhythmias is specifically excluded for both systems at this time. To date, the company's surgical ablation systems have been used in numerous institutions around the country including Baylor University Medical Center, Northwestern University Medical Center, University of Michigan Medical Center, Baptist Medical Center in San Antonio, TX, Scottsdale Healthcare - Osborn in Arizona, Banner Good Samaritan Medical Center in Phoenix, and Banner Baywood Heart Hospital in Mesa, AZ.
For more information visit www.medcvinc.com.
January 22, 2026 
